October 2024

Trick or Treat: Unmasking Antibody Reproducibility in Life Sciences

2024-10-04T14:48:45-04:00October 1st, 2024|Webinars|

October 31, 2024 | 11:00AM EST In this webinar, you will learn: How mAb irreproducibility could unknowingly impact your research outcomes Proven strategies to mitigate reproducibility risks when using research reagents The role of antibody sequencing in ensuring reproducibility with mAbs Rapid, cost-effective sequence confirmation for routine applications The next frontier: polyclonal [...]

September 2024

Agonist Antibody Challenges and Optimization

2024-10-01T17:08:33-04:00September 18th, 2024|Articles|

Written by: Jenna Kerry, MSc Published: September 17, 2024 Contents Introduction Agonistic Antibody Mechanism of Action Agonistic Antibody Development Challenges Optimizing Agonistic Antibodies Agonistic Antibody Development Introduction In the last decade, immunotherapy has rapidly transformed treatments for cancer, autoimmune disorders, and infectious diseases. While the [...]

August 2024

Interview with Dr. Thierry Le Bihan, Principal Scientist in Polyclonal Antibody Sequencing

2024-08-15T10:46:23-04:00August 1st, 2024|Articles|

Principal Scientist in Polyclonal Antibody Sequencing Dr. Thierry Le Bihan joined Rapid Novor as a Principal Scientist in 2018, tasked with leading a multidisciplinary team to develop a polyclonal antibody sequencing platform. Thierry brought extensive proteomics and mass spectrometry expertise from his previous roles as Director of Proteomics at The Campbell Family Institute [...]

July 2024

Antibody Discovery in Humans – Starting with Functional, Circulating Antibodies

2024-09-30T12:06:46-04:00July 23rd, 2024|Webinars|

In this webinar, you will: Explore how using a proteomics approach with REpAb® de novo sequencing accesses a larger diversity of antibodies, and enhances antibody discovery workflows. Case study on de novo sequencing functional and neutralizing antibodies directly from the serum of a Human patient vaccinated against SARS-CoV-2.  Discover novel antibody binders only [...]